Figure 1: Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity, Quality of Life and Clinical Outcomes in Patients With Heart Failure.

*A pre-specified analysis from the SELECT trial (HF composite outcome = cardiovascular death or HF hospitalisation/emergency visit).† Secondary outcomes of STEP HFpEF trials. ‡ Data from multicentre PRAISE HFpEF DM observational cohort study (HF composite outcome = HF hospitalisation and all-cause mortality). 6MWT = 6-min walking test; DT = deterioration time; GLP-1 RAs = Glucagon-like peptide-1 receptor agonists; HF = heart failure; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; HRQoL = health-related quality of life; KCCQ = Kansas City Cardiomyopathy Questionnaire; LV = left ventricle; LVEF = left ventricular ejection fraction; T2D = type 2 diabetes; RCT = randomised controlled trials.